
Max Healthcare Institute Gears Up for Q3 Reveal on 5th February; Check Key Expectations Here
Click and Sign Up to Get Live Updates on Q3 Results
Updated: 4 Feb 2026 • 6:00 pm
Posted by:

Max Healthcare Institute's Q3 results for FY26 are scheduled to be announced on 5th February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
Max Healthcare Institute Q3 Results 2026 Preview
- Max Healthcare Institute's revenue is expected to be in the range of ₹1,868.31 crore, a 9.42% YoY increase.
- Profit After Tax, or PAT, is projected to fall 15.26% YoY.
- Net profit is ₹238.80 crore, up 15.26% YoY
- EBITDA to fall 10.49%
Max Healthcare Institute Share Performance
- Over the past six months, Max Healthcare Institute's share price has fallen by 18.23% to ₹227.90.
- Moreover, over the past year, the stock has decreased by 12.93%.
- Despite this weak short-term performance, Max Healthcare Institute's stock has delivered a financially sound 470.59% return over the past 5 years.
- As of 4th February 2026, the stock traded at ₹1,022.50 per share.
Key Factors to Watch for Max Healthcare Institute Q3 Results FY26
- Revenue & Patient Volume: Track growth in total revenue and patient volumes, including occupied bed days.
- ARPOB & Margins: Monitor average revenue per occupied bed and EBITDA/net profit margins.
- Bed Occupancy & Specialty Mix: Assess occupancy rates and contribution from specialty departments.
- International Patients & New Facilities: Watch inflows from medical tourism and performance of newly operational hospitals.
- Management Outlook: Focus on expansion plans, cost management, and balance sheet health.
Final Thoughts
Max Healthcare Institute will announce its Q3 FY26 results on 5th February 2026. Analysts expect a 9.42% revenue growth, a 15.26% fall in PAT, and a 10.49% decline in EBITDA. Max Healthcare’s Q3 FY26 results, focus on revenue and patient volumes, ARPOB and margins, bed occupancy and specialty mix, international patient inflows, and management guidance on expansion and costs.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Archean Chemical Industries Gears Up for Q3 Reveal on 4th February; Check Key Expectations Here
Advent Hotels International Gears Up for Q3 Reveal on 4th February; Check Key Expectations Here
Andhra Paper Gears Up for Q3 Reveal on 4th February; Check Key Expectations Here
Apollo Tyres Gears Up for Q3 Reveal on 4th February; Check Key Expectations Here
Aptus Value Housing Gears Up for Q3 Reveal on 4th February; Check Key Expectations Here
Associated Alcohols & Breweries Gears Up for Q3 Reveal on 4th February; Check Key Expectations Here
Recent Articles

Vedanta Shares: Should You Buy After Hindustan Zinc Beats Q2 Estimates? Emkay Keeps Buy and a Rs 350 Target
21 October 2026

SpaceX Q3 2026 Results: Why Shares Jumped After a $4.4 Billion Profit and What Musk Said on the Tesla Merger
21 October 2026

Fortis Share Price: Sumeet Bagadia's Buy Call, Target and Stop-Loss After the Fall
21 October 2026

HDFC Bank Share Price: Anand Rathi Sees a Long Road to Catch Up with Peers
21 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Vedanta Shares: Should You Buy After Hindustan Zinc Beats Q2 Estimates? Emkay Keeps Buy and a Rs 350 Target
SpaceX Q3 2026 Results: Why Shares Jumped After a $4.4 Billion Profit and What Musk Said on the Tesla Merger
Fortis Share Price: Sumeet Bagadia's Buy Call, Target and Stop-Loss After the Fall
HDFC Bank Share Price: Anand Rathi Sees a Long Road to Catch Up with Peers
Paras Healthcare IPO: Hospital Occupancy, Profit and What Investors Should Check Before Bidding

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





